Intest Res.  2015 Jul;13(3):274-281. 10.5217/ir.2015.13.3.274.

Institutional Board Review for Clinical Investigations on Inflammatory Bowel Diseases: A Single-Center Study

• Park S
• Noh YH
• Rha SY
• Kim WH
• Cheon JH

• KMID: 2174485
• DOI: http://doi.org/10.5217/ir.2015.13.3.274

Abstract

BACKGROUND/AIMS
The growing volume and the diversity of clinical research has led to related laws and regulations as well as the Institutional Review Board (IRB) approval process becoming more stringent. To conduct clinical research efficiently and while following regulations, information about the IRB approval process and feedback is important for investigators. This has yet to be studied.
METHODS
We included 381 gastrointestinal disease research proposals (79 with inflammatory bowel disease [IBD], and 302 with non-IBD) reviewed by the IRB of Severance Hospital between January 2009 and December 2013. We retrospectively analyzed research characteristics including research risk levels, results of initial reviews, frequencies of continuing review, numbers of IRB comments, frequencies of IRB comments, and durations from submission to approval.
RESULTS
Investigators' decisions on risk level were higher in the IBD group than in the non-IBD group (P<0.05). Results of initial reviews, frequencies of continuing reviews, the numbers of IRB review comments, and durations from submission to approval were not different between the two groups, but IRB decisions on risk level were higher in the IBD group (P<0.05). In subgroup analysis, the number of IRB comments from initial review on informed consent forms and procedures as well were quest of more information were significantly higher in the IBD group than in the non-IBD group (P<0.001 and 0.01, respectively).
CONCLUSIONS
In Korea, rare diseases such as IBD require more information for the IRB process due to their distinct characteristics. IBD researchers should develop research protocols more carefully and make their research as subject-friendly as possible.

Keyword

Inflammatory bowel diseases; Institutional review board; Institutional review board recommendation

MeSH Terms

Consent Forms
Ethics Committees, Research
Gastrointestinal Diseases
Humans
Inflammatory Bowel Diseases*
Jurisprudence
Korea
Rare Diseases
Research Design
Research Personnel
Retrospective Studies
Social Control, Formal

Reference

1. Yang SK, Yun S, Kim JH, et al. Epidemiology of inflammatory bowel disease in the Songpa-Kangdong district, Seoul, Korea, 1986-2005: a KASID study. Inflamm Bowel Dis. 2008; 14:542–549. PMID: 17941073.

2. Thia KT, Loftus EV Jr, Sandborn WJ, Yang SK. An update on the epidemiology of inflammatory bowel disease in Asia. Am J Gastroenterol. 2008; 103:3167–3182. PMID: 19086963.

3. Park SJ, Kim WH, Cheon JH. Clinical characteristics and treatment of inflammatory bowel disease: a comparison of Eastern and Western perspectives. World J Gastroenterol. 2014; 20:11525–11537. PMID: 25206259.

4. Woodward B. Challenges to human subject protections in US medical research. JAMA. 1999; 282:1947–1952. PMID: 10580461.

5. World Medical Association Inc. Declaration of Helsinki. Ethical principles for medical research involving human subjects. J Indian Med Assoc. 2009; 107:403–405. PMID: 19886379.

6. Griggs RC, Batshaw M, Dunkle M, et al. Clinical research for rare disease: opportunities, challenges, and solutions. Mol Genet Metab. 2009; 96:20–26. PMID: 19013090.

7. Cheon JH, Kim YS, Ye BD, et al. Crohn's Disease Clinical Network and Cohort (CONNECT) study: the first step toward nationwide multicenter research of Crohn's disease in Korea. Intest Res. 2014; 12:173–175. PMID: 25349589.

8. Barber B, Lally JJ, Makarushka JL, Sullivan D. Research on human subjects: problems of social control in medical experimentation. New York: Russell Sage Foundation;1973.

9. Bartlett EE. International analysis of institutional review boards registered with the U.S. Office for human research protection. J Empir Res Hum Res Ethics. 2008; 3:49–56. PMID: 19385756.

10. Bell J, Whiton J, Connelly S. [Report]. Evaluation of NIH implementation of Section 491 of the Public Health Service Act, mandating a program of protection for research subjects (USA). Washington, D.C.: U.S. Department of Health and Human Services;1998.

11. Catania JA, Lo B, Wolf LE, et al. Survey of U.S. human research protection organizations: workload and membership. J Empir Res Hum Res Ethics. 2008; 3:57–69. PMID: 19122821.

12. Sansone RA, McDonald S, Hanley P, Sellbom M, Gaither GA. The stipulations of one institutional review board: a five year review. J Med Ethics. 2004; 30:308–310. PMID: 15173369.

13. Shah S, Whittle A, Wilfond B, Gensler G, Wendler D. How do institutional review boards apply the federal risk and benefit standards for pediatric research? JAMA. 2004; 291:476–482. PMID: 14747505.

14. McWilliams R, Hoover-Fong J, Hamosh A, Beck S, Beaty T, Cutting G. Problematic variation in local institutional review of a multicenter genetic epidemiology study. JAMA. 2003; 290:360–366. PMID: 12865377.

15. Burman W, Breese P, Weis S, Bock N, Bernardo J, Vernon A. Tuberculosis Trials Consortium. The effects of local review on informed consent documents from a multicenter clinical trials consortium. Control Clin Trials. 2003; 24:245–255. PMID: 12757991.

16. Lidz CW, Appelbaum PS, Arnold R, et al. How closely do institutional review boards follow the common rule? Acad Med. 2012; 87:969–974. PMID: 22622205.

17. Altman DG. Practical statistics for medical research. London: Chapman & Hall;1991.

18. Bosani M, Ardizzone S, Porro GB. Biologic targeting in the treatment of inflammatory bowel diseases. Biologics. 2009; 3:77–97. PMID: 19707398.

19. Kuhbacher T, Folsch UR. Practical guidelines for the treatment of inflammatory bowel disease. World J Gastroenterol. 2007; 13:1149–1155. PMID: 17451192.

20. Jeon HH, Lee HJ, Jang HW, et al. Clinical outcomes and predictive factors in oral corticosteroid-refractory active ulcerative colitis. World J Gastroenterol. 2013; 19:265–273. PMID: 23345950.

21. Johnston RD, Logan RF. What is the peak age for onset of IBD? Inflamm Bowel Dis. 2008; 14(Suppl 2):S4–S5. PMID: 18816745.